Advertisement
(Logo: http://www.newscom.com/cgi-bin/prnh/20070608/NEF043LOGO )
The first poster presentation entitled: "Brain microdialysate and plasmaconcentrations of Inosine during intravenous Inosine infusion in consciousrats" highlighted the results of a central nervous system (CNS) microdialysisstudy designed to measure the levels of Inosine in the brain duringintravenous infusion of high concentrations of Inosine. The results suggestthat Inosine infused intravenously was measurably able to cross the blood-brain barrier. Inosine is a nerve regenerative factor that has been shown topromote axon outgrowth in neurons and has potential to be used to treat CNSdisorders such as stroke, spinal cord injury and traumatic brain injury.
Advertisement
"The literature suggests that Inosine can cross the blood-brain barrier,however, no direct measurements of brain levels of Inosine during systemicdosing have been previously reported," commented Noel Cusack, Ph.D, Alseres'Senior Vice President of Preclinical Development. "This study shows that whenadministered intravenously using our new, highly-concentrated Inosineformulation, Inosine levels in the brain increased more than 600%, thusoffering a viable alternative to more invasive administration."
The second poster presentation entitled: "Brain and PlasmaPharmacokinetics of Three Dopamine Transporter (DAT)-selective Blockers AfterAdministration of a Range of Single Oral Doses in Conscious Mice" summarizedthe findings of a study to determine brain bioavailability following oraladministration of three highly-selective DAT Blockers. The data presentedhave shown that all three DAT blockers given orally were rapidly absorbed intothe blood and the brain and provided favorable brain-to-blood plasma ratios.
"Alseres' DAT blockers have previously been shown to mitigate Parkinson'sDisease symptoms in a non-human primate model of PD when given byintramuscular injection. But obviously oral dosing is generally a much moreconvenient route of routine administration," noted Dr. Cusack. "We believethat this study, using a range of oral doses for three DAT Blockers, hassuccessfully shown that these compounds are potentially attractive candidatesfor oral treatments of PD."
About Alseres Pharmaceuticals, Inc.
Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) is a biotechnology companyengaged in developing breakthrough regenerative therapeutics to treattraumatic injuries and degenerative diseases. The Company maintains a world-class intellectual property position in the field of regenerativetherapeutics. The Company's energy and focus is reflected in severalimportant initiatives. Cethrin(R), a recombinant-protein-based drug designedto promote nerve repair after acute spinal cord injury, demonstrated positiveinterim results in a Phase I/IIa clinical trial. The Company's research andpre-clinical programs include, Inosine for the treatment of spinal cord injuryand stroke, Oncomodulin for the treatment of ocular injury and disease andresearch programs directed at a number of regenerative therapies includingbone repair. The Company has a robust molecular imaging development programtargeting diagnosis of Parkinson's disease and potentially dementia and ADHD.The Company's lead molecular imaging product candidate is ALTROPANE(R) whichis in Phase III clinical trials for the diagnosis of Parkinsonian Syndromesincluding Parkinson's Disease. The Company has research collaborations withHarvard Medical School and Children's Hospital Boston.
Safe Harbor
The foregoing release contains certain forward-looking
